Immatics N.V.

Healthcare · Biotechnology · Germany

Last price 7.2 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 984.17M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy produ...